Hemochromatosis (HH) is usually inherited as autosomal recessive disease. The diagnosis is made by laboratory investigations (a high serum ferritin and transferrin saturation), by liver biopsy shows an elevated hepatic iron concentration (hemosiderin deposits characteristically appearing first in the hepatocytes in the periportal areas). The most common type of HH is caused by a mutation in the HFE Gene (Type 1-Classic Adult-Onset): Located on chromosome 6, The two main mutations are:

1. C282Y: The primary disease-causing variant. Being homozygous (inheriting two C282Y mutations—one from each parent) accounts for the majority of severe clinical cases.

2. H63D: A more common, lower-penetrance variant. Unlike the more severe C282Y mutation, being H63D homozygous rarely causes classic, heavy iron overload. Most people with this result never develop symptoms or store excess iron.

H63D Syndrome

Some individuals develop a distinct clinical picture known as H63D Syndrome; this can involve non-transferrin-bound iron (NTBI) issues where ferritin levels appear normal or low, yet transferrin saturation is high and symptoms still occur. H63D homozygotes have an increased risk of polyarthralgia, chondrocalcinosis, and osteoarthritis (especially in younger adults under 65).

Compound Heterozygosity

Inheriting the 2 different mutations together. The prevalence of heterozygous hereditary hemochromatosis is estimated to be about 6–14%. A compound heterozygote (inheriting one C282Y and one H63D) rarely causes clinical iron overload on its own — unmasking factors must typically be present:

Menopause or Cessation of Menstruation: This is the most common physiological unmasking factor in women. Regular menstruation and pregnancy naturally bleed off excess iron. Once menopause occurs, iron begin accumulating rapidly, "unmasking" the condition later in life than in men.

Aging (Accumulated Iron Burden): HH is a progressive disease. Symptoms typically do not appear until middle age (ages 40–60), when total body iron stores reach a critical tipping point and begin damaging organs like the liver, pancreas, and heart.

Alcohol Consumption: Alcohol acts as a massive disease accelerant. It decreases hepcidin (a hormone that suppresses iron absorption) and synergizes with tissue iron to unmask advanced liver disease, accelerating the development of cirrhosis or liver failure.

High Dietary Iron Intake or Vitamin C Supplementation: Consuming highly bioavailable iron or excessive Vitamin C (which drastically increases dietary iron absorption) accelerates iron loading and brings forward symptom onset.

Co-existing Liver Conditions: Chronic conditions like fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MASLD) or Non-alcoholic fatty liver (NAFL) and Chronic hepatitis C infections reduce the liver's resilience, unmasking symptoms at lower levels of iron overload.

Other Rare Genetic Variations

Juvenile Hemochromatosis (Type 2): A rare, severe form causing iron buildup and heart failure in adolescence or young adulthood (ages 15–30). It is caused by mutations in the HJV (hemojuvelin) or HAMP (hepcidin) genes.

Type 3 Hemochromatosis: Caused by mutations in the TfR2 (transferrin receptor 2) gene, presenting similarly to early-onset adult hemochromatosis.

Type 4 Hemochromatosis (Ferroportin Disease): Caused by mutations in the SLC40A1 gene. Unlike the other types, this form follows an autosomal dominant inheritance pattern rather than recessive.

Inheritance Pattern

Autosomal Recessive (Types 1, 2, and 3): A person must inherit one abnormal gene from both parents to be at risk for the condition.

Carriers: Because hemochromatosis is an autosomal recessive condition, people who inherit only one mutated gene are carriers (heterozygotes). They generally do not develop iron overload symptoms.

Low Penetrance: Having two mutated genes (such as C282Y homozygosity) means you have a genetic predisposition, but not everyone develops clinical illness or severe organ damage (known as variable or low clinical penetrance).

Mild, Non-Clinical Changes: While carriers rarely develop full-blown iron overload disease, biochemical studies show that some heterozygotes may experience very mild, insignificant elevations in their blood iron markers. For example, they might have a slightly higher serum ferritin or transferrin saturation percentage than people without any mutations, but these levels almost never rise high enough to cause tissue or organ damage.

Compound Heterozygosity: There is a difference between being a "simple" heterozygote (having one mutation and one perfectly normal gene) and a compound heterozygote. A compound heterozygote inherits two different mutations — most commonly one C282Y mutation and one H63D mutation. While still generally milder than inheriting two copies of the severe C282Y mutation, compound heterozygotes do face a higher risk of developing actual iron storage problems. Long-term exposure to small amounts of iron may play a role in atherogenesis and ischemia/reperfusion damage by catalyzing free radical formation, so even minimally increased iron stores in heterozygous HH could be detrimental and might explain the increased cardiovascular risk in heterozygous HH. The condition of hereditary hemochromatosis must therefore be managed through preventative lifestyle changes such as abstinence from alcohol and reduced iron intake, with recommendation for regular phlebotomy if symptoms are present.